Cargando…
Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation?
Human immunodeficiency virus type 1 (HIV) continues to be one of the most prevalent global health afflictions to date. The advent and introduction of combined antiretroviral therapy (cART) has made a significant impact on the course of infection. However, as patients are living longer, many HIV-asso...
Autores principales: | Davidson, Donna C, Jackson, Joseph W, Maggirwar, Sanjay B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906985/ https://www.ncbi.nlm.nih.gov/pubmed/24289660 http://dx.doi.org/10.1186/1742-2094-10-144 |
Ejemplares similares
-
Excess Soluble CD40L Contributes to Blood Brain Barrier Permeability In Vivo: Implications for HIV-Associated Neurocognitive Disorders
por: Davidson, Donna C., et al.
Publicado: (2012) -
Valproic Acid Inhibits the Release of Soluble CD40L Induced by Non-Nucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus Infected Individuals
por: Davidson, Donna C., et al.
Publicado: (2013) -
Modeling HIV-1 Induced Neuroinflammation in Mice: Role of Platelets in Mediating Blood-Brain Barrier Dysfunction
por: Jones, Letitia D., et al.
Publicado: (2016) -
Levels of human platelet-derived soluble CD40 ligand depend on haplotypes of CD40LG-CD40-ITGA2
por: Aloui, Chaker, et al.
Publicado: (2016) -
Induction of Apoptosis in Cancer Cells of pre-B ALL Patients
after Exposure to Platelets, Platelet-Derived
Microparticles and Soluble CD40 Ligand
por: Yaftian, Morteza, et al.
Publicado: (2018)